[8-K] InMed Pharmaceuticals Inc. Reports Material Event

Rhea-AI Filing Summary

InMed Pharmaceuticals (INM) appointed Neil Klompas to its board of directors, effective October 9, 2025, and increased the board size to five members. His term runs until immediately before the 2025 Annual General Meeting. The company noted there are no related party transactions or family relationships tied to his appointment.

Klompas will receive non-employee director compensation consistent with company policy, including an annual retainer of US$50,000, with potential additional amounts for committee service. InMed furnished a press release as Exhibit 99.1.

Insights

Corporate governance analyst

Routine board addition; neutral governance update.

InMed Pharmaceuticals added Neil Klompas as a director effective October 9, 2025 and expanded the board to five. The filing states no related party transactions or family relationships connected to the appointment.

Compensation follows the non-employee director program, including an annual retainer of US$50,000, with possible committee fees, and execution of a standard indemnification agreement.

The company also furnished a press release as Exhibit 99.1. This is an administrative governance change; investment impact is typically limited unless future committee roles are disclosed.

false 0001728328 A1 0001728328 2025-10-09 2025-10-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 9, 2025

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

British Columbia		001-39685		98-1428279
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

InMed Pharmaceuticals Inc. Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada		V6C 3E8
(Address of Principal Executive Offices)		(Zip Code)

Company’s telephone number, including area code: (604) 669-7207

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, no par value		INM		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On October 7, 2025, the board of directors (the “Board”) of InMed Pharmaceuticals Inc. (the “Company”) appointed Mr. Neil Klompas as a director and concurrently increased the size of the Board to five members, both effective as of October 9, 2025. Mr. Klompas may be appointed to one or more of the committees of the Board, but the appointments have not been determined at this time. Mr. Klompas’s term as a member of the Board will expire immediately before the Annual General Meeting to be held in 2025.

There are no arrangements nor understandings between Mr. Klompas, on the one hand, and the Company or any other persons, on the other hand, pursuant to which he was selected as a director of the Company. There are no related party transactions between the Company and Mr. Klompas (or any of his immediate family members) requiring disclosure under Item 404(a) of Regulation S-K. Mr. Klompas does not have any family relationship with any of the Company’s other directors or executive officers.

Mr. Klompas will be entitled to receive compensation for service as a non-employee director consistent with the Company’s non-employee director compensation program, which includes an annual retainer of US50,000 and may include additional amounts for serving as a Board committee member, if applicable. In connection with his appointment to the Board, Mr, Klompas executed the Company’s standard form of indemnification agreement for directors.

Item 7.01 Regulation FD Disclosure.

On October 9, 2025, the Company issued a press release announcing the appointment of Mr. Neil Klompas as a director. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

Exhibit No.		Description
99.1		Press Release filed October 9, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INMED PHARMACEUTICALS INC.
Date: October 10, 2025	By:	/s/ Eric A. Adams
		Eric A. Adams
		President and CEO

2

FAQ

What did INM announce regarding its board of directors?

InMed appointed Neil Klompas as a director effective October 9, 2025 and increased the board to five members.

When does Neil Klompas’s term as INM director end?

His term expires immediately before the 2025 Annual General Meeting.

What compensation will Neil Klompas receive as an INM director?

He will receive an annual non-employee director retainer of US$50,000, with potential additional amounts for committee service.

Are there related party transactions or family relationships disclosed for this appointment?

No. The filing states no related party transactions and no family relationships tied to the appointment.

Did INM issue a press release about the appointment?

Yes. A press release was furnished as Exhibit 99.1 on October 9, 2025.

Will Neil Klompas serve on INM board committees?

He may be appointed to one or more committees; appointments have not been determined at this time.